Core Laboratories Inc. /DE/

For the period ended Mar 31, 2026. Filed May 1, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 1, 2026

CLB$9.03+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at March 31, 2026 (Unaudited) and December 31, 2025

CONSOLIDATED BALANCE SHEETS

	March 31,2026	December 31,2025
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$22,819	$22,702
Accounts receivable, net of allowance for credit losses of $6,488 and $6,317 at 2026 and 2025, respectively	108,277	113,528
Inventories	57,784	54,496
Prepaid expenses	11,356	9,734
Income taxes receivable	6,917	7,270
Other current assets	7,218	6,935
TOTAL CURRENT ASSETS	214,371	214,665
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $319,112 and $320,707 at 2026 and 2025, respectively	99,985	99,447
RIGHT OF USE ASSETS	54,708	54,346
INTANGIBLES, net of accumulated amortization and impairment of $19,739 and $19,531 at 2026 and 2025, respectively	6,893	7,118
GOODWILL	105,796	105,789
DEFERRED TAX ASSETS, net	71,296	67,381
OTHER ASSETS	34,679	35,264
TOTAL ASSETS	$587,728	$584,010
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$39,982	$37,275
Accrued payroll and related costs	22,295	26,525
Taxes other than payroll and income	4,065	4,272
Unearned revenues	4,708	5,552
Operating lease liabilities	12,097	11,456
Income taxes payable	4,214	4,255
Other current liabilities	17,373	16,680
TOTAL CURRENT LIABILITIES	104,734	106,015
LONG-TERM DEBT, net	114,460	110,255
LONG-TERM OPERATING LEASE LIABILITIES	41,285	42,309
DEFERRED COMPENSATION	28,165	29,381
DEFERRED TAX LIABILITIES, net	8,073	7,995
OTHER LONG-TERM LIABILITIES	15,867	15,847
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding	—	—
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,048,268 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025	470	470
Additional paid-in capital	115,221	110,245
Retained earnings	171,413	172,662
Accumulated other comprehensive income (loss)	(5,754)	(5,806)
Treasury stock (at cost), 918,600 and 871,489 shares at 2026 and 2025, respectively	(12,464)	(11,585)
Total Core Laboratories Inc. shareholders' equity	268,886	265,986
Non-controlling interest	6,258	6,222
TOTAL EQUITY	275,144	272,208
TOTAL LIABILITIES AND EQUITY	$587,728	$584,010

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.